Effect of metformin in treatment of non-diabetic pulmonary tuberculosis patients
Not Applicable
- Conditions
- Health Condition 1: A150- Tuberculosis of lung
- Registration Number
- CTRI/2019/03/017926
- Lead Sponsor
- Veer Surendra Sai Institute of Medical Sciences and Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.New sputum positive cases
2.Non-diabetic (FBS <100 mg/dl & HbA1c < 5.7%
3.Not taking any other immunomodulator drugs.
Exclusion Criteria
1. Immunocompromised states such as Chronic debilitating diseases, HIV-AIDS
2. Hb% < 7
3. Any Drug resistant TB.
4. Impaired Liver or Renal function .
5. Respiratory Insufficiency/Hypoxia (peripheral oxygen saturation level <92% ).
6. Pregnancy / Lactating mother.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Sputum conversion of new sputum positive non-diabetic pulmonary tuberculosis patients <br/ ><br>2.Time taken for sputum conversionTimepoint: Every 15 days for a period of 2 months from initiation of therapy
- Secondary Outcome Measures
Name Time Method Effect of Metformin on: <br/ ><br>1.Symptoms of Pulmonary TB- cough, fever, weight loss, breathlessness and fatigue. <br/ ><br>2.Adverse effects in patients taking MET and ATT co-therapy <br/ ><br>Timepoint: Every 1 month after initiation of therapy.